The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial
Acute administration of the oral 5-HT1A receptor agonist buspirone, which is commonly used as an anxiolytic drug, may improve compromised lower esophageal sphincter function. In an open-label trial we assessed the effects of buspirone on esophageal motor function and symptoms in patients with esophageal involvement associated with systemic sclerosis (SSc). Thirty consecutive patients with SSc and symptomatic esophageal involvement, despite treatment with proton pump inhibitors, underwent high resolution manometry and chest computed tomography for assessment of motor function and esophageal dil... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Reihe/Periodikum: | Arthritis research & therapy |
Verlag/Hrsg.: |
London,
BioMed Central
|
Sprache: | Englisch |
ISSN: | 1478-6354 |
Weitere Identifikatoren: | doi: 10.1186/s13075-016-1094-y |
Permalink: | https://search.fid-benelux.de/Record/olc-benelux-198361520X |
URL: | NULL NULL |
Datenquelle: | Online Contents Benelux; Originalkatalog |
Powered By: | Verbundzentrale des GBV (VZG) |
Link(s) : | http://dx.doi.org/10.1186/s13075-016-1094-y
http://dx.doi.org/10.1186/s13075-016-1094-y |
Wird geladen...